Novel peptidomimics as angiotensin-converting enzyme inhibitors: a combinatorial approach (Q30845584)

27 June 2017

title

Novel peptidomimics as angiotensin-converting enzyme inhibitors: a combinatorial approach (English)

1 reference

27 June 2017

Manju Bala

1

1 reference

27 June 2017

M A Qadar Pasha

series ordinal

2

1 reference

27 June 2017

D K Bhardwaj

series ordinal

3

1 reference

27 June 2017

Santosh Pasha

series ordinal

4

1 reference

27 June 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

Bioorganic & Medicinal Chemistry

27 June 2017

published in

1 reference

27 June 2017

volume

10

1 reference

27 June 2017

issue

11

1 reference

27 June 2017

page(s)

3685-3691

1 reference

Structure and functions of human angiotensin I converting enzyme (kininase II).

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900166-9

7 January 2021

Angiotensin I converting enzyme and the changes in our concepts through the years. Lewis K. Dahl memorial lecture

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900166-9

7 January 2021

Cardiac angiotensin-converting enzyme activity in myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900166-9

7 January 2021

Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900166-9

7 January 2021

A new class of angiotensin-converting enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900166-9

7 January 2021

Synthesis and pharmacological activity of angiotensin converting enzyme inhibitors: N-(mercaptoacyl)-4-substituted-(S)-prolines

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900166-9

7 January 2021

Dual metalloprotease inhibitors. 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900166-9

7 January 2021

Vasopeptidase inhibitors: incorporation of geminal and spirocyclic substituted azepinones in mercaptoacyl dipeptides

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900166-9

7 January 2021

Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900166-9

7 January 2021

Peptidomimetic design

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900166-9

7 January 2021

Peptidomimetics and small-molecule drug design: towards improved bioavailability and in vivo stability

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900166-9

7 January 2021

High-diversity combinatorial libraries

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900166-9

7 January 2021

Combinatorial chemistry in drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900166-9

7 January 2021

Chemical ligands, genomics and drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900166-9

7 January 2021

Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900166-9

7 January 2021

Libraries of non-polymeric organic molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900166-9

7 January 2021

Families of metalloendopeptidases and their relationships

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900166-9

7 January 2021

Design of Specific Inhibitors of Angiotensin-Converting Enzyme: New Class of Orally Active Antihypertensive Agents

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900166-9

7 January 2021

Angiotensin-converting enzyme inhibitors: Medicinal chemistry and biological actions

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900166-9

7 January 2021

Recent developments in the design of angiotensin-converting enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900166-9

7 January 2021

Constrained peptides as binding entities

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900166-9

7 January 2021

General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900166-9

7 January 2021

Synthetic strategies in combinatorial chemistry

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900166-9

7 January 2021

Solid phase synthesis of partially protected and free peptides containing disulphide bonds by simultaneous cysteine oxidation-release from 2-chlorotrityl resin

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900166-9

7 January 2021

Angiotensin-converting enzyme assay optimization: influence of various buffers and their concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900166-9

7 January 2021

10.1016/S0968-0896(02)00166-9

Identifiers

DOI

1 reference

27 June 2017

1 reference